<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-QILBFZTL</identifier><date>2024</date><creator>Ivkovič, Jakob</creator><creator>Unk, Mojca</creator><relation>documents/doc/Q/URN_NBN_SI_doc-QILBFZTL_001.pdf</relation><relation>documents/doc/Q/URN_NBN_SI_doc-QILBFZTL_001.txt</relation><format format_type="issue">2, ahead of print</format><format format_type="volume">28</format><format format_type="type">article</format><format format_type="extent">str. 1-21</format><identifier identifier_type="DOI">10.25670/oi2024-009on</identifier><identifier identifier_type="ISSN">1408-1741</identifier><identifier identifier_type="COBISSID_HOST">208991747</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-QILBFZTL</identifier><language>slv</language><publisher>Onkološki inštitut Ljubljana</publisher><source>Onkologija (Ljubljana)</source><rights>BY</rights><subject language_type_id="eng">cancerogenesis</subject><subject language_type_id="slv">črevesni mikrobiom</subject><subject language_type_id="eng">gut microbiome</subject><subject language_type_id="eng">immune checkpoint inhibitors</subject><subject language_type_id="eng">immunotherapy</subject><subject language_type_id="slv">imunoterapija</subject><subject language_type_id="slv">kancerogeneza</subject><subject language_type_id="slv">zaviralci imunskih nadzornih točk</subject><title>Črevesni mikrobiom pri bolnikih z rakom</title><title>Gut microbiome in cancer patients</title></Record>